서한슬 ((재)씨젠의료재단)

백제현 ((재)씨젠의료재단)

백제현 ((재)씨젠의료재단)

서한슬 ((재)씨젠의료재단)

양원석 ((재)씨젠의료재단)

Parathyroid hormone (PTH) is a peptide hormone secreted by the parathyroid glands and plays a crucial role in regulating calcium levels in the blood and bone metabolism. Accurate monitoring and management of PTH levels are critical for effective diagnosis and treatment in hyperparathyroidism and hypoparathyroidism. However, current antibody-based PTH assays have shown discrepancies among multiple assays due to the issues such as antibody cross-reactivity. Therefore, there is a need to enhance the accuracy of measurements of intact PTH for the treatment planning of parathyroid-related disorders.

Beyond antibody-based PTH assays, mass spectrometry-based assays have gained attention as alternative methods providing higher accuracy. In this study, we established a mass spectrometry-based intact PTH (Protein-MRM) assay and peptide PTH (Peptide-MRM) assay using triple quad mass spectrometry. Additionally, we compared the Peptide-MRM method with the Protein-MRM method for PTH quantification. For method optimization, we utilized the PTH 1-84 standard material (WHO 95/646) as an internal standard in each assay. The intact PTH assay was validated for linearity, accuracy, and recovery. The linear range of Intact PTH was approximately 10 to 1000 pg/mL, and the recovery of each interval was verified. The comparison study of Protein-MRM and Peptide-MRM assays for PTH measurement showed a high correlation between the two methods.

We expect that our mass-spectrometry-based PTH assays (Protein and Peptide-MRM) for PTH measurement may contribute significantly to the standardization of the intact PTH assay, potentially antibody-based assays (2nd or 3rd generation PTH assays).